Giovanni Carbognin

Giovanni Carbognin

Auto-generated profile, based on publicly available information

Giovanni Carbognin

Department of Radiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
CPCarlo Procacci
Carlo Procacci
CBCarlo Biasiutti
Carlo Biasiutti
GCGiovanni Carbognin
Giovanni Carbognin
SASimone Accordini
Simone Accordini
EBEgidio Bicego
Egidio Bicego
AMAlec J. Megibow
Alec J. Megibow
The purpose of this work was to evaluate the capabilities of CT to accurately characterize cystic tumors of the pancreas. Two observers retrospectively evaluated the CT exams of 100 cystic masses of the pancreas, with pathological confirmation. The two observers, blinded about clinical information and the final diagnosis, tried to categorize the lesions according to well established morphologic features. Statistical analysis was performed to measure the agreement between each radiologist and the consensus diagnosis and to evaluate the usefulness of certain CT findings in differentiating one type of cystic pancreatic neoplasm from another. Serous cystadenoma was better diagnosed by CT [Youden misclassification index (Ymi) = 0.72] than mucinous cystic tumor (Ymi = 0.44) and solid pseudopapillary tumor (cystic variant) (Ymi = 0.47). As patients with previous history of pancreatitis were excluded from the study, CT findings allowed correct characterization of only 60% of cystic pancreatic masses. Among the remaining 40%, 15-20% of the wrong diagnoses could not be corrected by means of CT, given the patterns shown by the tumors. In 20-25% of the cases, a nonspecific diagnosis of cystic mass was made.

1 November 1999 in RadioGraphics
Verified
Journal Article
Closed access
CPCarlo Procacci
Carlo Procacci
AMAlec J. Megibow
Alec J. Megibow
GCGiovanni Carbognin
Giovanni Carbognin
AGAlessandro Guarise
Alessandro Guarise
ESElide Spoto
Elide Spoto
GPGian Franco Pistolesi
Gian Franco Pistolesi
Intraductal papillary mucinous tumor (IPMT) of the pancreas was identified and classified only recently. IPMT has a primarily intraductal, papillomatous growth pattern, which is associated with excessive mucin secretion and results in progressive ductal dilatation or cyst formation. The tumor occurs in four forms: segmental or diffuse involvement of the main pancreatic duct and macrocystic or microcystic involvement of a branch duct. In the past, many IPMTs may have been misdiagnosed as chronic pancreatitis because of their generally benign behavior. The correct diagnosis, once achieved only with endoscopic retrograde cholangiopancreatography (ERCP), can now be made with noninvasive imaging modalities, particularly computed tomography (CT) and magnetic resonance (MR) imaging. ERCP remains the imaging modality of choice for diagnosis of IPMT. With ERCP, the communication between the cystically dilated ductal segment or branch duct and the main pancreatic duct is easily demonstrated. However, reflux of contrast material due to an excess of mucin or an enlarged papillary orifice hinders filling of the ductal tree. Filling defects due to mucin globs or mural nodules are also important clues to the diagnosis. Bulging of the papilla into the duodenal lumen is virtually pathognomonic of IPMT and is well demonstrated with CT or MR imaging.

9 December 2015 in The Oncologist
Verified
Journal Article
Open access
PDF file
AIAlessandro Inno
Alessandro Inno
GBGiuseppe Bogina
Giuseppe Bogina
MTMonica Turazza
Monica Turazza
LBLaura Bortesi
Laura Bortesi
SDSimona Duranti
Simona Duranti
SGStefania Gori
Stefania Gori
Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline- and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast.

19 April 2001 in European Radiology
Verified
Journal Article
Closed access
PDF file
CPCarlo Procacci
Carlo Procacci
GCGiovanni Carbognin
Giovanni Carbognin
SASimone Accordini
Simone Accordini
CBCarlo Biasiutti
Carlo Biasiutti
AGAlessandro Guarise
Alessandro Guarise
RMRoberto De Marco
Roberto De Marco

1 May 2006 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
NTNicola Tessitore
Nicola Tessitore
GMGiancarlo Mansueto
Giancarlo Mansueto
GLGiovanni Lipari
Giovanni Lipari
VBValeria Bedogna
Valeria Bedogna
STStefano Tardivo
Stefano Tardivo
ALAntonio Lupo
Antonio Lupo
Surgery is the traditional treatment for juxta-anastomotic stenoses in forearm arteriovenous fistulas (AVF), but percutaneous transluminal angioplasty (PTA) is a suitable alternative. No prospective comparative trials between the two have been reported to date, however. A retrospective analysis of prospectively, concurrently collected data was performed to compare the outcome and cost of surgery and PTA in the preemptive repair of juxta-anastomotic stenosis in lower forearm AVF. Sixty-four AVF with >50% venous juxta-anastomotic stenosis were considered: 21 were treated surgically (11 proximal neo-anastomosis and 10 polytetrafluoroethylene interposition graft) and 43 by PTA. After treatment, AVF were monitored by quarterly ultrasound dilution access blood flow measurement. End points were restenosis and procedure failure rate (re-intervention by another technique or access loss), and determinants were analyzed using Cox hazard model. Initial procedural success was 100% for surgery and 95% for PTA (P = 0.539). Restenosis rate was 0.168 and 0.519 events/AVF-year for surgery and PTA, respectively (P = 0.009). The type of procedure was the only variable that was significantly associated with restenosis, the adjusted relative risk being 2.77-fold higher (95% confidence interval 1.07 to 7.17; P = 0.036) after PTA than surgery. The procedure failure rate was 0.110 and 0.097 events/AVF-year for surgery and PTA, respectively (P = 0.736). The cost profile also was similar for the two procedures. This prospective comparative study confirms a higher restenosis rate after PTA than surgery, but with strict surveillance for restenosis, the two procedures show similar assisted primary patency and cost, suggesting that they should be considered equally valid, complementary alternatives in the preemptive treatment of juxta-anastomotic stenosis in forearm AVF.

1 October 2001 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
AMA. J. Megibow
A. J. Megibow
FLF. P. Lombardo
F. P. Lombardo
AGA. Guarise
A. Guarise
GCG. Carbognin
G. Carbognin
JSJ. Scholes
J. Scholes
CPC. Procacci
C. Procacci